2026
Journal
Real-time in-season monitoring of adult influenza vaccination coverage rates in Germany: results from a repeated cross-sectional online survey
Vaccine. 2026;88:128765. doi: 10.1016/j.vaccine.2026.128765.
Evidence. Insights. Access.
Evidence strategy for every stage of the product lifecycle.
From first-in-human to loss of exclusivity, MarksMan works alongside Medical Affairs, Market Access, Commercial and BD leaders to decide what evidence each stage demands — anticipating HTA, JCA, CMS and payer expectations — and then to build it.
- 01Early DevelopmentTPP stress-testEvidence gaps
- 02Pre-LaunchSLR · NMA · ModelsJCA / HTA readiness
- 03Launch & AccessDossiers · AMCPIRA · MFN
- 04In-MarketRWE studiesHCP · Patient voice
- 05Lifecycle & PortfolioExpansion · LOEBD due diligence
Where are you in the lifecycle?
Every stage asks a different evidence question. We answer the one in front of you — and anticipate the next.
01Phase I – II
Early Development
Decide what the asset must prove — before the pivotal trial is designed
“Will the planned Phase III endpoints and comparators satisfy HTA and JCA assessors, or only regulators?”
02Phase III – Submission
Pre-Launch
Build the evidence package that survives assessment in every target market
“Which comparators will the JCA PICO scoping and national HTA bodies actually demand?”
03Approval – First 18 months
Launch & Access
Land the dossiers, navigate policy and secure reimbursement market by market
“Will Medicare select this asset for IRA negotiation — and is the evidence package ready if it does?”
04Growth & Defence
In-Market
Generate the real-world evidence and insight that keep the asset winning
“Which real-world questions will payers, regulators and guideline committees ask next — and which data source can credibly answer them?”
05Expansion – LOE – BD
Lifecycle & Portfolio
Extend the asset, defend it at loss of exclusivity and choose the next one wisely
“Which new indications or populations can the existing evidence base credibly support — and which need fresh generation?”
Who we advise
Strategy for the departments that own the evidence
We don't wait for a brief. We work with functional leaders to define the questions worth answering, then bring the multidisciplinary team — physicians, health economists, statisticians, medical writers — to answer them.
Medical Affairs
Prove medical impact, capture field and HCP insights and detect scientific signals early.
Market Access & HEOR
Anticipate HTA and payer expectations — from EU joint clinical assessments to US IRA negotiation, MFN pricing and AMCP dossiers — and build the evidence to meet them.
Commercial & Launch
Read the competitive landscape, understand what drives HCP adoption, and sequence launches with confidence.
Clinical Development & RWE
Design real-world studies whose evidence regulators and payers will accept — and hear the patient voice directly.
Business Development & Licensing
Assess partnering assets through the EU JCA and US payer-value lens before the deal is signed — so licensed science becomes commercial success.
Publications & Biostatistics
Turn data into peer-reviewed evidence — with the analytical rigour and publication strategy that make each paper count.
How we engage
From diagnosis to recommendation — one accountable partner
01
Diagnose
We audit your evidence, competitive and stakeholder landscape against what decision-makers will demand.
02
Strategise
Together we define the value narrative, evidence-generation plan and metrics that prove progress.
03
Generate
Our HEOR, RWE, analytics and medical writing teams deliver the evidence — to HTA-grade standards.
04
Recommend
You receive a strategic report — clear insights, options and recommendations on what your department should do next, and why.
Capabilities
Ten capabilities behind every stage
HEOR & Global Market Access Strategy
Evidence strategy, economic modelling, HTA positioning and multi-market launch readiness
ExploreReal World Evidence Strategy
RWE roadmaps, study design and real-world insight generation
ExploreMedical Affairs Strategy
Scientific strategy, insight generation and field-medical enablement
ExploreCompetitive Intelligence
Landscape strategy and continuous competitor monitoring
ExploreAdvanced Analytics
Analytical strategy, biostatistics and AI-enabled evidence workflows
ExploreScientific Communications
Publication strategy, manuscripts and congress presence
ExploreSocial Media Listening & Patient Voice
Patient and caregiver voice, sentiment and unmet-need intelligence from public conversations
ExploreHCP Voice & Intelligence
Evidence-calibrated intelligence on what clinicians think, and why
ExploreUS Market Access & Pricing Policy
AMCP dossiers, IRA negotiation readiness, MFN and CMS policy strategy
ExploreEU HTA & Joint Clinical Assessment
JCA readiness, PICO strategy and national adaptation across Europe
ExploreAI-assisted, consultant-led — where it adds value
Some questions deserve deeper analysis. For those, our consultants draw on in-house AI tools.
Not every project needs them. Where they strengthen a recommendation — an HTA or IRA readiness check, a patient- or HCP-voice analysis, a competitive scenario model — we apply them inside our own workflows. What you receive is the same in every case: a strategic report with clear insights and recommendations.
Thought leadership
We publish what we practise
2026
Conference
Social Media Conversations on GLP-1 Therapies for Obesity: Real-World Experiences and Treatment Narratives
at ISPOR, 17-20 May – 2026, Philadelphia, USA
2026
Conference
Social Media Sentiment Toward Anti-Amyloid Therapies in Early Alzheimer’s Disease: Implications for Real-World Evidence and Decision-Making
at ISPOR, 17-20 May – 2026, Philadelphia, USA
2026
Conference
An Automated Social Media Listening Analysis of Conversations on CGRP Preventive Therapies in Migraine
at ISPOR, 17-20 May – 2026, Philadelphia, USA
Facing an HTA submission, a launch or an evidence gap?
Start with a 45-minute strategy conversation. We'll tell you candidly what evidence you need — and what you don't.